China leads the world with the fastest growth rates in economy, health care spending, drug expenditure and the business environment for drug development and registration has matured, with an established State Food and Drug Administration and improved intellectual property protection. In this session, we plan to provide the latest update on the landscape for clinical development and registration, as well as commercial opportunities, of biologics products in China.



Objectives:

Understand the current landscape of therapeutic biologics in the China market, as well as short-range and midterm perspectives.

Highlight value-chain analysis of R&D through commercialization of biologics in China, focusing on differences between process in China and the U.S./EU.

Understand IP protection for biologics in China.